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Early prediction of the outcome of patients with
sepsis could be helpful in guiding therapies but
remains challenging. Presepsin, a new sepsis
biomarker whose elevation as early as day 1 is
well correlated with 28-day mortality, could be
considered to this end.sepsis since it is known that delayed ICU admissionPredicting prognosis in sepsis is of paramount importance.
Clinical assessments and the usual biological surrogates for
organ dysfunction are still widely used and help us to pro-
vide care for critically ill patients with sepsis in everyday
practice. We thus hope to optimize therapies and provide
the most appropriate care to our patients by considering
every severity endpoint as a danger signal that will trigger
the most suitable interventions, in an attempt to improve
survival. As suggested in this issue of Critical Care by
Masson and colleagues [1], sepsis biomarkers and espe-
cially newly discovered ones such as presepsin may give
us the opportunity to earn time.
As previously shown, the main objective in this setting is
clearly to intervene early and in an appropriate manner, es-
pecially regarding empirical antibiotic therapy and fluid
management [2]. Dampening an overwhelming inflamma-
tory response is also desirable, but so far this objective has
remained beyond our reach. Accordingly, sepsis severity is
strongly related to the inflammatory response resulting
from the ambivalent interaction between innate immunity
and pathogens [3]. Physicians thus have to rack their brains
to find the best way to assess such imbalances in the host
response to infection. The aim is to accurately predict
organ failure before it becomes obvious, by which time it is
very often too late. This makes sense if interventions likely* Correspondence: pierre-emmanuel.charles@chu-dijon.fr
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© BioMed Central Ltd.2014to prevent end-organ dysfunction and immunomodulatory
therapies could then be implemented, leading in turn to an
improved survival.
The challenge is therefore to find biomarkers that give
the physician accurate information regarding the risk of
a poor outcome within the very first hours of manage-
ment. This point is especially relevant in the emergency
room in order to improve the triage of patients with
could worsen the outcome.
An additional benefit we could expect from sepsis bio-
markers is to assess the efficacy of our management, es-
pecially the appropriateness of our first-line antibiotic
therapy, which is known to be critical in septic shock
[4]. The biomarker’s kinetics should be quickly and
tightly related to the patient’s outcome, thus allowing
prompt therapy adjustment if necessary (that is, before
any microbiological data are available).
Masson and colleagues [1] present the results of an in-
teresting and timely study that aimed to evaluate the
prognostic value of presepsin in septic patients admitted
to the ICU [1]. This is an ancillary study of a large ran-
domized controlled trial that compared albumin with
crystalloids for the early management of patients with
sepsis. The authors showed that, compared with procal-
citonin (PCT), presepsin measured on day 1 predicted
90-day mortality in these selected patients more accur-
ately than, and thus independently from, other potential
confounders. In addition, presepsin kinetics were also
related to the outcome, suggesting a close relationship
between the biomarker course and the effectiveness of
both host response and the therapies used. This bio-
marker therefore seems to fulfill the above-mentioned
requirements for any sepsis biomarker we would like
to use as a marker of prognosis. However, further data
are required before stronger conclusions can be drawn.
Moreover, these results illustrate another key point.
The ‘all-in-one’ concept, in fact, does not suit sepsis bio-
markers very well, and one should not have too many
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to clinical assessment, is considered one of the best diag-
nosis tools for sepsis. However, as shown in the present
study and an earlier study [5], the magnitude of PCT
elevation on day 1 does not reliably predict the outcome
in patients with sepsis. Taken together, these findings
suggest that one given biomarker should not be used to
answer more than one given relevant question. Indeed,
we have shown that, despite having excellent diagnostic
value, some biomarkers, like CD64 neutrophil expression,
failed to predict outcome [6]. Conversely, one recently pub-
lished study showed that PCT performed better as a diag-
nosis tool than presepsin in patients with suspected sepsis
in the emergency room [7]. As a result, these two bio-
markers should be used in combination. However, cost and
availability issues might compromise such practices.
Sepsis is a dynamic event, and the clinical evolution
within the very first days in the ICU is clearly related to sur-
vival. To be useful, biomarkers should be able to predict de-
veloping or worsening organ failure; if this is not the case,
clinical judgment and sequential organ failure assessment
(SOFA) score calculation, for instance, will have to be
enough. PCT kinetics was shown to be tightly related to
clinical outcome and thus better than calculating the SOFA
score daily and measuring blood lactate variations [5]. The
authors failed to demonstrate such a relationship in the
present study, whereas the presepsin time course did seem
to correlate nicely with outcome. However, it should be
pointed out that PCT concentrations were not measured
daily, but only on days 1, 2, and 7. The half-life of presepsin
may be longer than that of PCT and the kinetics there-
fore slower. Nonetheless, further studies are needed be-
fore any firm conclusions can be drawn.
One last expectation related to sepsis biomarkers is their
ability to customize antibiotic duration. Monitoring PCT has
been shown to be effective regarding this point in various
clinical conditions, including sepsis and septic shock, without
compromising the outcome, at least apparently [8]. The au-
thors suggest that presepsin could be useful to this end since
its course is related to the outcome. This issue deserves fu-
ture investigation, and comparison with PCT is essential.
In conclusion, although many correlations have been
established between the net values or kinetics (or both) of
some biomarkers and outcomes in patients with sepsis,
there is little convincing evidence to support their use as
such in everyday practice. Only one trial, the Procalcitonin
And Survival Study, was designed to this end, but it failed
to demonstrate any improvement in the outcome when
PCT elevation beyond an alert value was used as a trigger
for the implementation of new antibiotic therapy [9]. How-
ever, an effort should be made to design new studies able
to test such hypotheses, using existing and new bio-
markers such as presepsin. Actually, evidence rather than
belief is still required.Abbreviations
PCT: Procalcitonin; SOFA: Sequential organ failure assessment.
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